Financings in Brief: Mallinckrodt
This article was originally published in The Gray Sheet
Executive Summary
Mallinckrodt: Plans to expand its ongoing share repurchase program by $250 mil. "to share proceeds" with shareholders from the divestiture of its animal health business. Mallinckrodt announced July 1 that it completed the sale of its animal health business Mallinckrodt Veterinary to Schering-Plough for $405 mil. in cash. Mallinckrodt, which announced its decision to sell the veterinary business in August 1996, unveiled plans for the sale to Schering-Plough in May...
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.